Search
Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation
The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).
Read moreHARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies
HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…
Read moreHighlights from the SWG
On November 24, 2022, the SWG on Red Cells and Iron held its annual Business meeting virtually which was chaired by Prof. Ali Taher and Prof. Achille Iolascon.
Read moreASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
Training vital for new era of patient-centric healthcare
Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…
Read moreHighlights of Past EHA (HOPE) Middle East and North Africa (MENA) 2021 - report
The sixth HOPE MENA, with highlights of the EHA Annual Congress, successfully concluded September 23-24. Fully virtual for the second year in a row, the program was compiled together with eight regional partner societies.
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »